Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's Disease

Next Previous
Trial Profile

An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's Disease

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gantenerumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Open RoAD
  • Sponsors Roche

Most Recent Events

  • 09 Feb 2023 This trial has been completed in Denmark, according to European Clinical Trials Database record.
  • 09 Feb 2023 This trial has been discontinued in Poland, according to European Clinical Trials Database record.
  • 29 Jan 2023 This trial has been completed in Netherland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top